Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization

Peter Abadir, Ammasi Periasamy, Robert M. Carey, Helmy M. Siragy

Research output: Contribution to journalArticle

Abstract

Angiotensin II type 2 (AT2R) or bradykinin B2 (B2R) receptor activation enhances NO production. Recently, we demonstrated enhancement of NO production when AT2R and B2R are simultaneously activated in vivo. However, the mechanism involved in this enhancement is unknown. Using confocal fluorescence resonance energy transfer microscopy, we report the distance between the AT2R and B2R in PC12W cell membranes to be 50±5 Å, providing evidence and quantification of receptor heterodimerization as the mechanism for enhancing NO production. The rate of AT2R-B2R heterodimer formation is largely a function of the degree of AT2R-B2R expression. The physical association between the dimerized receptors initiates changes in intracellular phosphoprotein signaling activities leading to phosphorylation of c-Jun terminal kinase, phosphotyrosine phosphatase, inhibitory protein κBα, and activating transcription factor 2; dephosphorylation of p38 and p42/44 mitogen-activated protein kinase and signal transducer inhibitor of transcription 3; and enhancing production of NO and cGMP. Controlling the expression of AT2R-B2R, consequently influencing their biologically active dimerization, presents a potential therapeutic target for the treatment of hypertension and other cardiovascular and renal disorders.

Original languageEnglish (US)
Pages (from-to)316-322
Number of pages7
JournalHypertension
Volume48
Issue number2
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Activating Transcription Factor 2
Angiotensin Type 2 Receptor
Bradykinin B2 Receptors
Fluorescence Resonance Energy Transfer
Protein Tyrosine Phosphatases
Phosphoproteins
Mitogen-Activated Protein Kinase 1
Dimerization
Transducers
Angiotensin II
Microscopy
Phosphotransferases
Phosphorylation
Cell Membrane
Hypertension
Kidney
Therapeutics
IgA receptor

Keywords

  • Angiotensin
  • Bradykinin
  • Nitric oxide
  • Receptors, bradykinin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. / Abadir, Peter; Periasamy, Ammasi; Carey, Robert M.; Siragy, Helmy M.

In: Hypertension, Vol. 48, No. 2, 08.2006, p. 316-322.

Research output: Contribution to journalArticle

Abadir, Peter ; Periasamy, Ammasi ; Carey, Robert M. ; Siragy, Helmy M. / Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. In: Hypertension. 2006 ; Vol. 48, No. 2. pp. 316-322.
@article{33693d5266864c94aafa16880885ce24,
title = "Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization",
abstract = "Angiotensin II type 2 (AT2R) or bradykinin B2 (B2R) receptor activation enhances NO production. Recently, we demonstrated enhancement of NO production when AT2R and B2R are simultaneously activated in vivo. However, the mechanism involved in this enhancement is unknown. Using confocal fluorescence resonance energy transfer microscopy, we report the distance between the AT2R and B2R in PC12W cell membranes to be 50±5 {\AA}, providing evidence and quantification of receptor heterodimerization as the mechanism for enhancing NO production. The rate of AT2R-B2R heterodimer formation is largely a function of the degree of AT2R-B2R expression. The physical association between the dimerized receptors initiates changes in intracellular phosphoprotein signaling activities leading to phosphorylation of c-Jun terminal kinase, phosphotyrosine phosphatase, inhibitory protein κBα, and activating transcription factor 2; dephosphorylation of p38 and p42/44 mitogen-activated protein kinase and signal transducer inhibitor of transcription 3; and enhancing production of NO and cGMP. Controlling the expression of AT2R-B2R, consequently influencing their biologically active dimerization, presents a potential therapeutic target for the treatment of hypertension and other cardiovascular and renal disorders.",
keywords = "Angiotensin, Bradykinin, Nitric oxide, Receptors, bradykinin",
author = "Peter Abadir and Ammasi Periasamy and Carey, {Robert M.} and Siragy, {Helmy M.}",
year = "2006",
month = "8",
doi = "10.1161/01.HYP.0000228997.88162.a8",
language = "English (US)",
volume = "48",
pages = "316--322",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization

AU - Abadir, Peter

AU - Periasamy, Ammasi

AU - Carey, Robert M.

AU - Siragy, Helmy M.

PY - 2006/8

Y1 - 2006/8

N2 - Angiotensin II type 2 (AT2R) or bradykinin B2 (B2R) receptor activation enhances NO production. Recently, we demonstrated enhancement of NO production when AT2R and B2R are simultaneously activated in vivo. However, the mechanism involved in this enhancement is unknown. Using confocal fluorescence resonance energy transfer microscopy, we report the distance between the AT2R and B2R in PC12W cell membranes to be 50±5 Å, providing evidence and quantification of receptor heterodimerization as the mechanism for enhancing NO production. The rate of AT2R-B2R heterodimer formation is largely a function of the degree of AT2R-B2R expression. The physical association between the dimerized receptors initiates changes in intracellular phosphoprotein signaling activities leading to phosphorylation of c-Jun terminal kinase, phosphotyrosine phosphatase, inhibitory protein κBα, and activating transcription factor 2; dephosphorylation of p38 and p42/44 mitogen-activated protein kinase and signal transducer inhibitor of transcription 3; and enhancing production of NO and cGMP. Controlling the expression of AT2R-B2R, consequently influencing their biologically active dimerization, presents a potential therapeutic target for the treatment of hypertension and other cardiovascular and renal disorders.

AB - Angiotensin II type 2 (AT2R) or bradykinin B2 (B2R) receptor activation enhances NO production. Recently, we demonstrated enhancement of NO production when AT2R and B2R are simultaneously activated in vivo. However, the mechanism involved in this enhancement is unknown. Using confocal fluorescence resonance energy transfer microscopy, we report the distance between the AT2R and B2R in PC12W cell membranes to be 50±5 Å, providing evidence and quantification of receptor heterodimerization as the mechanism for enhancing NO production. The rate of AT2R-B2R heterodimer formation is largely a function of the degree of AT2R-B2R expression. The physical association between the dimerized receptors initiates changes in intracellular phosphoprotein signaling activities leading to phosphorylation of c-Jun terminal kinase, phosphotyrosine phosphatase, inhibitory protein κBα, and activating transcription factor 2; dephosphorylation of p38 and p42/44 mitogen-activated protein kinase and signal transducer inhibitor of transcription 3; and enhancing production of NO and cGMP. Controlling the expression of AT2R-B2R, consequently influencing their biologically active dimerization, presents a potential therapeutic target for the treatment of hypertension and other cardiovascular and renal disorders.

KW - Angiotensin

KW - Bradykinin

KW - Nitric oxide

KW - Receptors, bradykinin

UR - http://www.scopus.com/inward/record.url?scp=33748160210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748160210&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000228997.88162.a8

DO - 10.1161/01.HYP.0000228997.88162.a8

M3 - Article

C2 - 16754789

AN - SCOPUS:33748160210

VL - 48

SP - 316

EP - 322

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -